Related Experiment Video
Updated: Jun 25, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
The management of hepatitis C
1Section of Hepatobiliary Diseases and Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida Gainesville, FL, USA.
Minerva Gastroenterologica E Dietologica
|February 13, 2009
Summary
Hepatitis C treatment is improving, with new targeted therapies offering personalized options. Research is advancing to overcome limitations of current hepatitis C (HCV) treatments and side effects.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C (HCV) affects over 170 million globally, posing a significant public health challenge.
- Current HCV treatments have limitations, including a cure rate of only 40% and potential side effects.
- Viral kinetics during treatment may guide personalized HCV therapy.
Purpose of the Study:
- To review current therapies for Hepatitis C.
- To discuss recent advances in novel Hepatitis C treatments.
- To explore the potential of Specifically Targeted Antiviral Therapy for HCV (STAT-C).
Main Methods:
- Literature review of current and emerging Hepatitis C treatments.
- Analysis of viral kinetic data in treatment response.
- Discussion of drug development for STAT-C.
Main Results:
- Current Hepatitis C therapies are not ideal and have side effects.
- Tailored therapy based on viral kinetics shows promise.
- Specifically Targeted Antiviral Therapy for HCV (STAT-C) compounds are under development.
Conclusions:
- Advances in understanding the Hepatitis C virus (HCV) genome and lifecycle are driving new therapeutic strategies.
- Personalized medicine approaches, guided by viral kinetics, are crucial for improving HCV treatment outcomes.
- The development of STAT-C represents a significant step towards more effective and safer Hepatitis C management.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...